{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:05:13Z","timestamp":1764738313273,"version":"3.46.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The review begins with epidemiology studies that show an increased incidence of later onset myasthenia gravis (MG) and higher short-term mortality rates, especially in females, compared with the general population in Denmark. In the United States, a study showed increased mortality especially in older patients, and there was racial disparity. In France, a study showed higher mortality with male gender, older age, and higher comorbidities. Economic burden is addressed in another article. Regarding clinical features, light sensitivity in MG is discussed along with differentiating thyroid eye disease symptoms and signs from those of ocular MG. MG-specific measures are highlighted with consensus recommendations for their use. Several articles contain data regarding diagnostic laboratory assays and test sensitivity and specificity among other measures. The role of thymectomy in older patients with MG is considered. The medical treatment section addresses corticosteroid regimens, intravenous immunoglobulin as maintenance therapy, a phase 3 study of the recently approved neonatal Fc receptor (FcRN) blocker nipocalimab, use of complement inhibitors and FcRN blockers in general, regimens for efgartigimod, and positive studies on the interleukin-16 receptor monoclonal antibody (Ab) satralizumab and the CD19 B-cell-depleting monoclonal Ab inebilizumab.<\/jats:p>","DOI":"10.1097\/cnd.0000000000000536","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:00:17Z","timestamp":1764738017000},"page":"34-44","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["What is in the Neuromuscular Junction Literature?"],"prefix":"10.1097","volume":"27","author":[{"given":"Joshua","family":"Smith","sequence":"first","affiliation":[{"name":"Departments of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lacomis","sequence":"additional","affiliation":[{"name":"Departments of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA; and"},{"name":"Pathology (Neuropathology), University of Pittsburgh School of Medicine, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20251203","doi-asserted-by":"crossref","first-page":"e210139","DOI":"10.1212\/WNL.0000000000210139","article-title":"Changes in myasthenia gravis incidence in Denmark from 1985 to 2021: a nationwide population-based study","volume":"104","author":"Jul Jarb\u00e6k Nielsen","year":"2025","journal-title":"Neurology"},{"key":"R2-20251203","doi-asserted-by":"crossref","first-page":"e213745","DOI":"10.1212\/WNL.0000000000213745","article-title":"Mortality in Myasthenia gravis in Denmark from 1985 to 2020: a population-based cohort study","volume":"104","author":"Jul Jarb\u00e6k Nielsen","year":"2025","journal-title":"Neurology"},{"key":"R3-20251203","doi-asserted-by":"crossref","first-page":"e213505","DOI":"10.1212\/WNL.0000000000213505","article-title":"Demographic and geographic trends in myasthenia gravis-related mortality in the United States, 1999-2022","volume":"104","author":"Al-Salahat","year":"2025","journal-title":"Neurology"},{"key":"R4-20251203","doi-asserted-by":"crossref","first-page":"e16518","DOI":"10.1111\/ene.16518","article-title":"Tracking myasthenia gravis severity over time: insights from the French health insurance claims database","volume":"32","author":"Attarian","year":"2025","journal-title":"Eur J Neurol"},{"key":"R5-20251203","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/mus.28313","article-title":"The economic burden of myasthenia gravis (MG): a survey of affected people and their families","volume":"71","author":"Yoder","year":"2025","journal-title":"Muscle Nerve"},{"key":"R6-20251203","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/mus.28386","article-title":"Light sensitivity in myasthenia gravis: clinical characteristics and impact on quality of life","volume":"71","author":"Sabatelli","year":"2025","journal-title":"Muscle Nerve"},{"key":"R7-20251203","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/WCO.0000000000001339","article-title":"Thyroid eye disease and ocular myasthenia gravis","volume":"38","author":"Shabto","year":"2025","journal-title":"Curr Opin Neurol"},{"key":"R8-20251203","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/mus.28282","article-title":"Longitudinal relationships between free-living activities, fatigue, and symptom severity in myasthenia gravis using cohort and individualized models","volume":"71","author":"Dimmick","year":"2025","journal-title":"Muscle & nerve"},{"key":"R9-20251203","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/mus.28417","article-title":"Standardization of myasthenia gravis outcome measures in clinical practice: a report of the mgfa task force","volume":"72","author":"Ruzhansky","year":"2025","journal-title":"Muscle Nerve"},{"key":"R10-20251203","doi-asserted-by":"crossref","first-page":"e210150","DOI":"10.1212\/WNL.0000000000210150","article-title":"Multicenter validation of the ocular myasthenia gravis rating scale questionnaire","volume":"104","author":"Wong","year":"2025","journal-title":"Neurology"},{"key":"R11-20251203","doi-asserted-by":"crossref","first-page":"e213498","DOI":"10.1212\/WNL.0000000000213498","article-title":"Risk of false acetylcholine receptor autoantibody positivity by radioimmunoprecipitation assay in clinical practice","volume":"104","author":"Zara","year":"2025","journal-title":"Neurology"},{"key":"R12-20251203","doi-asserted-by":"crossref","first-page":"e213612","DOI":"10.1212\/WNL.0000000000213612","article-title":"False positive acetylcholine receptor antibody testing in clinical practice A Bayesian tale","volume":"104","author":"Jones","year":"2025","journal-title":"Neurology"},{"key":"R13-20251203","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"key":"R14-20251203","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"J Neuroimmunol"},{"key":"R15-20251203","doi-asserted-by":"crossref","first-page":"123449","DOI":"10.1016\/j.jns.2025.123449","article-title":"Prevalence and course of muscle-specific receptor tyrosine kinase (MuSK) antibodies in myasthenia gravis: a retrospective study","volume":"472","author":"Stahl","year":"2025","journal-title":"J Neurol Sci"},{"key":"R16-20251203","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1212\/WNL.33.10.1316","article-title":"Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity","volume":"33","author":"Besinger","year":"1983","journal-title":"Neurology"},{"key":"R17-20251203","doi-asserted-by":"crossref","first-page":"e70123","DOI":"10.1111\/ene.70123","article-title":"Testing for acetylcholine receptor and muscle-specific tyrosine kinase antibodies by fixed cell-based assay in clinical practice: positive predictive value for myasthenia gravis","volume":"32","author":"Li","year":"2025","journal-title":"Eur J Neurol"},{"key":"R18-20251203","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"key":"R19-20251203","doi-asserted-by":"crossref","first-page":"e70048","DOI":"10.1111\/ene.70048","article-title":"Can Non-thymomatous late-onset myasthenia gravis benefit from thymectomy? A systematic review and meta-analysis","volume":"32","author":"Chen","year":"2025","journal-title":"Eur J Neurol"},{"key":"R20-20251203","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/1409983","article-title":"Association between initial corticosteroid regimen, and treatment response time in acetylcholine receptor antibody-positive myasthenia gravis","volume":"2024","author":"Kim","year":"2024","journal-title":"Acta Neurol Scand"},{"key":"R21-20251203","doi-asserted-by":"crossref","first-page":"e16463","DOI":"10.1111\/ene.16463","article-title":"Persistent symptoms, exacerbations and drug side effects despite treatment in myasthenia gravis","volume":"32","author":"Reyes-Leiva","year":"2025","journal-title":"Eur J Neurol"},{"key":"R22-20251203","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/mus.28289","article-title":"Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: a multicenter, double-blind, placebo-controlled trial","volume":"71","author":"Bril","year":"2025","journal-title":"Muscle Nerve"},{"key":"R23-20251203","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi","year":"2025","journal-title":"Lancet Neurol"},{"key":"R25-20251203","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"R24-20251203","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/jnnp-2024-334086","article-title":"Efgartigimod efficacy and safety in refractory myasthenia gravis: UKs first real-world experience","volume":"96","author":"Moniz Dion\u00edsio","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R26-20251203","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/mus.28334","article-title":"Individualized dosing of efgartigimod in patients with generalized myasthenia gravis: clinical experience at a single center","volume":"71","author":"Silvestri","year":"2025","journal-title":"Muscle Nerve"},{"key":"R27-20251203","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp-2024-334404","article-title":"C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis","volume":"96","author":"Huntemann","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R28-20251203","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1474-4422(24)00514-3","article-title":"Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"24","author":"Habib","year":"2025","journal-title":"Lancet Neurol"},{"key":"R29-20251203","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa2501561","article-title":"A phase 3 Trial of inebilizumab in generalized myasthenia gravis","volume":"392","author":"Nowak","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:00:20Z","timestamp":1764738020000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000536","relation":{},"ISSN":["1522-0443","1537-1611"],"issn-type":[{"value":"1522-0443","type":"print"},{"value":"1537-1611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}